Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release: BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine

12/16/2020 | 03:00am EDT
   -- Supply agreement reflects both companies' shared commitment and efforts 
      to achieve vaccine accessibility and affordability in China 
   -- A local Phase 2 clinical trial of mRNA COVID-19 vaccine candidate 
      BNT162b2 is on-going in Jiangsu, China 
BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") and 
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or 
"Group"; Stock Code: 600196.SH, 02196.HK) today announced an agreement 
to supply Mainland China with an initial 100 million doses of their 
BNT162 mRNA-based vaccine candidate against COVID-19 in 2021, subject to 
regulatory approval. Initial supply will be delivered from BioNTech's 
production facilities in Germany. 
   "We would like to thank the Chinese government and National Medical 
Products Administration for their commitment and trust in our vaccine 
development efforts to help address this global pandemic threat," said 
Ugur Sahin, M.D., CEO and Co-founder of BioNTech. "This joint 
development effort with Fosun Pharma is a testament to the importance of 
global cooperation and reflects our strategy to supply our vaccine 
globally. This agreement is an important step toward our shared goal of 
bringing a safe and efficacious vaccine to people worldwide." 
   "Since the outbreak of the COVID-19 epidemic, we have been working 
closely with BioNTech. With the support of the Joint Prevention and 
Control Mechanism of the State Council, especially the National Medical 
Products Administration, the National Health Commission, the Ministry of 
Science and Technology and other relevant authorities, the R&D and 
clinical trial of our COVID-19 mRNA vaccine in China has been moved 
forward rapidly. On the premise of ensuring the safety and effectiveness 
of the vaccine, we actively support the marketing of the vaccine in 
China. The BNT162b2 mRNA vaccine is a successful model of international 
R&D collaboration," Wu Yifang, Chairman and CEO of Fosun Pharma said. 
"We are pleased to reach the supply agreement with BioNTech, which is an 
important step in Fosun Pharma and BioNTech's efforts to achieve vaccine 
accessibility and affordability in China." 
   In March 2020, BioNTech and Fosun Pharma announced their strategic 
collaboration to work jointly on the development and commercialization 
of a potential COVID-19 vaccine based on BioNTech's mRNA technology 
   On November 24, 2020, the companies initiated a Phase 2 clinical trial 
of vaccine candidate BNT162b2 in Jiangsu Province, China. The trial 
commenced with the recruitment of 960 healthy participants, between 18 
to 85 years old, to assess the safety and immunogenicity of the vaccine 
candidate and to support future Biologic License Application (BLA) in 
   About BioNTech 
   Biopharmaceutical New Technologies is a next generation immunotherapy 
company pioneering novel therapies for cancer and other serious 
diseases. The Company exploits a wide array of computational discovery 
and therapeutic drug platforms for the rapid development of novel 
biopharmaceuticals. Its broad portfolio of oncology product candidates 
includes individualized and off-the-shelf mRNA-based therapies, 
innovative chimeric antigen receptor T cells, bi-specific checkpoint 
immuno-modulators, targeted cancer antibodies and small molecules. Based 
on its deep expertise in mRNA vaccine development and in-house 
manufacturing capabilities, BioNTech and its collaborators are 
developing multiple mRNA vaccine candidates for a range of infectious 
diseases alongside its diverse oncology pipeline. BioNTech has 
established a broad set of relationships with multiple global 
pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal 
Health, Genentech, a member of the Roche Group, Regeneron, Genevant, 
Fosun Pharma, and Pfizer. For more information, please visit 
   About Fosun Pharma 
   Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun 
Pharma"; stock code: 600196.SH, 02196.HK) is a leading healthcare group 
in China. Fosun Pharma has built a strong root in China and developed a 
global operation strategy, with pharmaceutical manufacturing and R&D 
being the largest and core business segment, together with strong 
presences in medical devices and diagnostics, healthcare services, 
pharmaceutical distribution and retail. 
   With R&D innovation as core driving factor, Fosun Pharma continues to 
optimize its pharmaceutical operations across both innovative and 
generic drugs. The company has established international R&D centers for 
excellence in areas such as innovative small molecule drugs, high-value 
generic drugs, biologics, and cell-therapy. 
   Under guidance of our 4IN strategy (Innovation, Internationalization, 
Integration and Intelligentization), Fosun Pharma follows the brand 
concept of Innovation for Good Health and strives to be a leading 
enterprise in the global pharmaceutical and healthcare markets. 
   For more information, please visit: 
   Forward-looking Statements of BioNTech 
   This press release contains "forward-looking statements" of BioNTech 
within the meaning of the Private Securities Litigation Reform Act of 
1995. These forward-looking statements may include, but may not be 
limited to, statements concerning: BioNTech's efforts to combat 
COVID-19; the collaboration between BioNTech and Fosun Pharma to develop 
a potential COVID-19 vaccine; our expectations regarding the potential 
characteristics of BNT162b2 in our Phase 2/3 trial and/or in commercial 
use based on data observations to date; the expected time point for 
additional readouts on efficacy data of BNT162b2 in our Phase 2/3 trial; 
the nature of the clinical data, which is subject to ongoing peer review, 
regulatory review and market interpretation; the timing for submission 
of data for, or receipt of, any marketing approval or Emergency Use 
Authorization; our contemplated shipping and storage plan, including our 
estimated product shelf-life at various temperatures; and the ability of 
BioNTech to supply the quantities of BNT162 to support clinical 
development and, if approved, market demand, including our production 
estimates for 2020 and 2021. Any forward-looking statements in this 
press release are based on BioNTech current expectations and beliefs of 
future events, and are subject to a number of risks and uncertainties 
that could cause actual results to differ materially and adversely from 
those set forth in or implied by such forward-looking statements. These 
risks and uncertainties include, but are not limited to: the ability to 
meet the pre-defined endpoints in clinical trials; competition to create 
a vaccine for COVID-19; the ability to produce comparable clinical or 
other results, including our stated rate of vaccine effectiveness and 
safety and tolerability profile observed to date, in the remainder of 
the trial or in larger, more diverse populations upon commercialization; 
the ability to effectively scale our productions capabilities; and other 
potential difficulties. 
   For a discussion of these and other risks and uncertainties, see 
BioNTech's Quarterly Report for the Three and Nine Months Ended 
September 30, 2020, filed as Exhibit 99.2 to its Current Report on Form 
6-K filed with the SEC on November 10, which is available on the SEC's 
website at 
www.sec.gov. All information in this press release is as of the date of 
the release, and BioNTech undertakes no duty to update this information 
unless required by law. 
   BioNTech's Media Relations 
   Jasmina Alatovic 
   Director Global External Communications 
   +49 89 62 81 75 46 
   Fosun Pharma's Media Relations 
   Barney Liu 
   Deputy Director of Media and Public Relations 
   Tel: +86 21-3398 7123 

(END) Dow Jones Newswires

December 16, 2020 03:00 ET (08:00 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
BAYER AG -0.79% 50.11 Delayed Quote.4.06%
BIONTECH SE 3.41% 351.81 Delayed Quote.331.56%
GENMAB A/S 1.86% 2902 Delayed Quote.15.67%
NASDAQ COMP. 0.55% 14761.294551 Real-time Quote.13.85%
PFIZER, INC. 3.91% 45.68 Delayed Quote.24.10%
SANOFI -0.35% 86.45 Real-time Quote.9.85%
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. 5.24% 86.71 End-of-day quote.60.60%
All news about BIONTECH SE
05:57pASTRAZENECA : Chilean study shows variations in success of COVID-19 vaccines
04:03pSECTOR UPDATE : Health Care Stocks Extending Gains Ahead of Tuesday Close
01:43pSECTOR UPDATE : Health Care Stocks Advancing Tuesday
08/02European ADRs Move Higher in Monday Trading
08/02BIONTECH : Berenberg Bank Adjusts BioNTech PT to $400 From $235, Maintains Buy R..
08/02BIONTECH : Corporate Presentation August 1 2021
08/02BIONTECH : Corporate Presentation
08/02BIONTECH : to Report Second Quarter Financial Results and Operational Update on ..
08/02PRESS RELEASE : BioNTech to Report Second Quarter Financial Results and Operatio..
08/02PFIZER : Should I Get the Covid-19 Vaccine While Pregnant or Breastfeeding? Expe..
More news
Sales 2021 13 071 M 15 504 M 15 504 M
Net income 2021 7 590 M 9 002 M 9 002 M
Net cash 2021 8 581 M 10 178 M 10 178 M
P/E ratio 2021 9,79x
Yield 2021 -
Capitalization 71 595 M 84 970 M 84 919 M
EV / Sales 2021 4,82x
EV / Sales 2022 5,32x
Nbr of Employees 2 200
Free-Float 87,3%
Duration : Period :
BioNTech SE Technical Analysis Chart | BNTX | US09075V1026 | MarketScreener
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 12
Last Close Price 296,44 €
Average target price 165,41 €
Spread / Average Target -44,2%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Ízlem TŘreci Chief Medical Officer
Sierk P÷tting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE331.56%82 168
WUXI APPTEC CO., LTD.41.52%69 241
BEIGENE, LTD.26.72%30 464